Research Highlight | Published:

Anti-PD1 in the wonder-gut-land

Cell Research volume 28, pages 263264 (2018) | Download Citation

Subjects

After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , et al. Science 2015; 348:124–128.

  2. 2.

    , , , et al. Science 2013; 342:971–976.

  3. 3.

    , , , et al. Science 2013; 342:967–970.

  4. 4.

    , , , et al. Science 2015; 350:1079–1084.

  5. 5.

    , , , et al. Science 2015; 350:1084–1089.

  6. 6.

    , , , et al. Cell 2017; 171:1015–1028.

  7. 7.

    , , , et al. Science 2018; 359:91–97.

  8. 8.

    , , , et al. Science 2018; 359:97–103.

  9. 9.

    , , , et al. Science 2018; 359:104–108.

  10. 10.

    , , , et al. Microbiome 2017; 5:71.

Download references

Author information

Affiliations

  1. Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

    • Marie Vetizou
    •  & Giorgio Trinchieri

Authors

  1. Search for Marie Vetizou in:

  2. Search for Giorgio Trinchieri in:

Corresponding author

Correspondence to Giorgio Trinchieri.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/cr.2018.12